Key clinical point: Rapid work-up and targeted therapy and immunotherapy boost survival in patients with anaplastic thyroid cancer.
Major finding: Median survival for patients in a specialized program who received targeted therapy and immunotherapy now stands at 16 months, with 43% of patients surviving 2 years or more.
Study details: A single-center study of 479 patients receiving care for anaplastic thyroid cancer before and after implementation of a comprehensive treatment approach that includes targeted therapy and immunotherapy, when appropriate.
Disclosures: Dr. Maniakas reported no conflicts of interest.
Maniakas A et al. ATA 2019, Short Call Oral Abstract 9.